| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | -0.016 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |